60 related articles for article (PubMed ID: 23111671)
21. Lack of tolerable treatment options for patients with schizophrenia.
Citrome L; Eramo A; Francois C; Duffy R; Legacy SN; Offord SJ; Krasa HB; Johnston SS; Guiraud-Diawara A; Kamat SA; Rohman P
Neuropsychiatr Dis Treat; 2015; 11():3095-104. PubMed ID: 26719694
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.
Ye W; Montgomery W; Kadziola Z; Liu L; Xue H; Stensland MD; Treuer T
Neuropsychiatr Dis Treat; 2014; 10():869-78. PubMed ID: 24876779
[TBL] [Abstract][Full Text] [Related]
23. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
24. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
25. Early prediction of antipsychotic nonresponse among patients with schizophrenia.
Leucht S; Busch R; Kissling W; Kane JM
J Clin Psychiatry; 2007 Mar; 68(3):352-60. PubMed ID: 17388703
[TBL] [Abstract][Full Text] [Related]
26. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.
Samara MT; Leucht C; Leeflang MM; Anghelescu IG; Chung YC; Crespo-Facorro B; Elkis H; Hatta K; Giegling I; Kane JM; Kayo M; Lambert M; Lin CH; Möller HJ; Pelayo-Terán JM; Riedel M; Rujescu D; Schimmelmann BG; Serretti A; Correll CU; Leucht S
Am J Psychiatry; 2015 Jul; 172(7):617-29. PubMed ID: 26046338
[TBL] [Abstract][Full Text] [Related]
27. Antipsychotic treatment response in schizophrenia.
Gardner KN; Bostwick JR
Am J Health Syst Pharm; 2012 Nov; 69(21):1872-9. PubMed ID: 23111671
[TBL] [Abstract][Full Text] [Related]
28. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
29. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
Haddad PM; Correll CU
Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
[TBL] [Abstract][Full Text] [Related]
30. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
[TBL] [Abstract][Full Text] [Related]
31. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.
Suzuki T; Remington G; Mulsant BH; Uchida H; Rajji TK; Graff-Guerrero A; Mimura M; Mamo DC
Psychiatry Res; 2012 May; 197(1-2):1-6. PubMed ID: 22429484
[TBL] [Abstract][Full Text] [Related]
32. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Ben Gharbia M; Garnier M; Llorca PM
Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
